Mon, Sep 22, 2014, 12:59 AM EDT - U.S. Markets open in 8 hrs 31 mins


% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • bbritt311 bbritt311 Jun 27, 2013 7:52 AM Flag

    Not asking to be attacked...

    Just really trying to wrap my head around it.... what does ONCS have that is proprietary? If they are licensing the technology from INO, what is ONCS offering that would make a large pharma company possibly want to create a partnership?

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Your a lazy bum, nothing more! Go hit the NET and do the DD. Your sitting on a goldmine and you don't even know about it!! LOL.

    • A poster below snidely suggests spending time on Google to research the issue. First do a search for "electroporation" then search "immunotherapy" and you will see Oncosec's position as related tp proprietary property.

    • Right now, there are two things I am trying to wrap my head around regardless of what strides they are making with Immunopluse. 1) the price per share has fallen below the December issue share price, and 2) I believe they stated they would try and have a partner for NeoPulse by the end of the first quarter and no news on that progress. Two things to put on the "cons" list.

      Sentiment: Hold

    • Funny on one wants to answer you. I don't see what ONCS has that will produce value. No takers for Neopulse is quite telling.

      • 2 Replies to jairy47
      • I am an amateur.

        My take is that ONCS has a non-exclusive license meaning that they could have some competition or maybe just some competition in electroporation niches. They have demonstrated that they can manufacture a medical device that meets or exceeds standards set by the EU, and it appears they are the leaders in proving electroporation technology if only in cancer tumors. Cancer therapies are big money and this company could be the leading electroporation company in the world. There was a Seeking Alpha article detailing your question, bbritt around December 2012. Try googling for it. I would link it but you know this board won't allow it.

        I might be confused but I thought Neopulse is Immunopulse using a different drug. The drug is an old cancer drug. In other words Neopulse is using old drugs while Immunopulse is using cutting edge tech to trigger the immune system to help. They also have begun pre-clinical trials on emerging immunotherapy drugs that haven't even been approved, but are promising. It shows that they are evolving with the drugs, rather than relying solely on yesterday's drugs.

        In other words, even though Neopulse has shown enough benefit to be an approved therapy in the EU, maybe companies are waiting for the new model to come out instead of driving the 1980's Honda.

        Some of this information may involve wishful thinking, or it may accidentally be spot on. I strongly suggest finding the Seeking Alpha article late last year which discusses many details involving your good question.

      • Nobody wants to spend their time stating the obvious to somebody who can't do basic research for themself. If britt wants an answer, he can spend 30 minutes on google for Christ's sake. And also, Neopulse is just a "side dish" for this company. Immunopulse has been their main project since Day #1, and that's straight from the CEO himself.

    • Quite are asking to be attacked..

    • Do some research and you will find out for yourself. Why should we all educate you, if you can't do your own basic DD?

0.5301-0.0149(-2.73%)Sep 19 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.